Cost of Novel Heart Failure Therapies: Is the Juice Worth the Squeeze?

This session will focus on heart failure innovations, their costs, and strategies to mitigate the financial barriers that prevent patients from accessing innovative therapies. It will include a debate on whether the cost of these therapies is justified, with an exploration of development costs to frame the value proposition. Following the debate, the session will provide practical advice on translating innovative heart failure therapies from research into clinical practice. The final segments will discuss strategies to reduce the financial burden of these therapies and ensure long-term affordability and accessibility for patients.

Agenda

• Moderator - Brad Williams, PharmD
• Moderator - Susan Bionat, DNP, FHFSA
• Price of Progress: New Heart Failure Therapies Are Worth It - Paul Heidenreich, MD, MS, FHFSA
• Strategies to Overcome Financial Toxicity: The Present - Viet Le, PA-C, HF-Cert
• Strategies to Overcome Financial Toxicity: The Present - TBD
• Opportunities & Initiatives to Improve Affordability: The Future - James Coons, PharmD
• Panel Discussion